Conversely, other studies showed that SOCS1 promoter methylation is associated with several conditions such as liver [44] and gastric [45] cancer, multiple myeloma [46], myeloproliferative neoplasm [47], lymphoma [48], pancreatic ductal neoplasms [49] and development of in-stent restenosis (ISR) after percutaneous coronary intervention [50]. Here, SOCS1 is linked to plasma cell myeloma.